rVSV pseudotyped EBOV GP

Product Description

rVSV pseudotyped EBOV GP is available at Gentaur for Next Week Delivery.

Product Type: protein

Host: N/A

Clonality: N/A

Applications: Neutralization

Description: Recombinant Vesicular Stomatitis Virus pseudotyped Ebola glycoprotein (rVSV
pseudotyped EBOV GP) system in which the G protein of VSV has been deleted, replaced with
firefly luciferase and used to produce VSV pseudotypes containing the envelope glycoprotein
of Ebola virus. Since the infectivity of rVSV pseudotyped EBOV GP is restricted to a single
round of replication, analyses of viral entry can be performed using just biosafety level 2 (BSL-2)
containment. Infectivity and neutralization of infectivity can be measured by luciferase activity.

Storage: -80°C

Size: 20 µl @ 1.97E+08 RLU/mL is supplied in Advanced DMEM supplemented with 1% Fetal Bovine Serum, L-glutamine and
Penicillin/Streptomycin, sufficient for one 96-well assay.

Relevance: This rVSV contains Ebola Virus glycoprotein and serves as a tool to enhance
filovirus research performed using just biosafety level 2 (BSL-2) containment.

Anti-EBOV human mAb KZ52, starting at 3 µg/mL
followed by serial dilutions, was incubated with the
rVSV pseudotyped with EBOV GP, for one hour
prior to adding to Vero cells. Infectivity was
determined the next day by assessing luciferase
activity. Percent neutralization was calculated
based on the control (rVSV pseudotyped with
EBOV GP, alone)

References:
1. Whitt, M.A., Generation of VSV
pseudotypes using recombinant DeltaGVSV for studies on virus entry,
identification of entry inhibitors, and
immune responses to vaccines. J. Virol.
Methods, 2010. 169(2): p. 365-74.
2. Howell, K.A., et al., Cooperativity Enables
Non-neutralizing Antibodies to Neutralize
Ebolavirus. Cell Reports, 2017. 19(2): p.
413-424.